Plus   Neg

5 Top Gainers In Healthcare Sector (AVEO, EDAP, ZYNE...)

pharmaup march02 lt

The following are some of today's top gainers in the pharma/biotech sector.

1. AVEO Pharmaceuticals Inc. (AVEO)

Gained 42.34% to close Tuesday's (Apr.2) trading at $1.58.

News: AVEO and Biodesix announced positive results from their phase Ib trial evaluating ficlatuzumab with cytarabine in patients with relapsed and refractory acute myeloid leukemia.

Of 12 patients who received ficlatuzumab and cytarabine at the maximally tolerated dose, one of whom was non-evaluable, 6 achieved a complete response (CR). The maximally tolerated dose was 20 mg/kg of ficlatuzumab on day 1 followed by 2 g/m2 cytarabine daily on days 2-7.

Of 18 patients enrolled in the study, 17 were evaluable and 9 achieved a CR.


EDAP is a revenue-generating medical device company.

Gained 42.14% to close Tuesday's trading at $4.25.

News: The Company announced financial results for the fourth quarter and full year 2018 and provided a strategic and operational update.

The Company recorded a net profit for the fourth quarter 2018 of €1.0 million (USD 1.2 million), or a profit of €0.04 per share compared to a net loss of €0.1 million (USD 0.1 million), or a loss of €0.00 per share in the year-ago period.

Total revenue for the fourth quarter of 2018 was €13.3 million (USD 15.1 million), an increase of 25.0% compared to €10.6 million (USD 12.6 million) for the fourth quarter of 2017.

3. Sangamo Therapeutics Inc. (SGMO)

Sangamo is a genomic medicine company.

Gained 28.96% to close Tuesday's trading at $12.29.

News: Sangamo and Pfizer Inc. (PFE) announced interim data from their Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.

According to the study results, SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) levels across the four dosage cohorts.

The Safety Monitoring Committee has recommended cohort expansion at the 3e13 vg/kg dose.

4. ADMA Biologics Inc. (ADMA)

Gained 24.32% to close Tuesday's trading at $5.06.

News: The Company's ASCENIV, Immune Globulin Intravenous, Human - slra 10% Liquid, has received FDA approval.

ASCENIV, formerly referred to as RI-002, has been approved for the treatment of Primary Humoral Immunodeficiency Disease in adults and adolescents (12 to 17 years of age).

The Company anticipates having the product available for commercial launch during the second half of 2019.

5. Zynerba Pharmaceuticals Inc. (ZYNE)

Gained 20% to close Tuesday's trading at $6.48.

News: Ladenburg analyst Michael Higgins has reiterated a Buy rating on ZYNE, with a price target of $26.

Clinical Trials & Near-term Catalysts:

-- A pivotal trial of ZYN002 in Fragile X Syndrome, dubbed CONNECT-FX, is underway, with topline results expected in the second half of 2019.
-- A phase II clinical trial evaluating ZYN002 in children and adolescents (three through 17 years) with developmental and epileptic encephalopathies, dubbed BELIEVE 1, is ongoing, with topline data expected in the third quarter of 2019.
-- The Company expects to initiate an open-label Phase 2 study in pediatric patients with Autism Spectrum Disorder in Australia in the first half of 2019.
-- A phase II study in pediatric patients with 22q is expected to be initiated in Australia in the first half of 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT